VA must add non-opioid pain drugs to formulary within 18 months
S. 3209 — NOPAIN for Veterans Act · Filed by Shelley Capito (R-WV) · 27 cosponsors · Introduced Nov 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the VA to add newly approved non-opioid pain medications to its formulary (list of covered drugs) within one year of FDA approval or when Medicare begins paying for them separately, whichever comes first. It defines non-opioid pain drugs as those that don't act on opioid receptors and are approved to treat acute or post-surgical pain. The bill bars the VA from using funds from the Cost of War Toxic Exposures Fund to pay for this expansion.
Why we flagged it
The bill's core function is to mandate VA inclusion of non-opioid pain medications in its formulary on a defined timeline, directly expanding treatment options for veterans. This is a straightforward public-health measure aimed at reducing opioid dependence in the VA system.
What the text implies
- The 18-month FDA-approval clock may incentivize faster VA adoption of newer drugs before Medicare payment pathways are established, potentially creating a gap where VA covers drugs before broader CMS guidance exists.
- Barring use of the Cost of War Toxic Exposures Fund (section 324) for this expansion may signal that non-opioid pain management is not classified as a war-related health need, potentially limiting funding for veterans with service-connected pain conditions.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers of non-opioid pain medications; FDA-approved drug developers in acute/post-surgical pain space